Eicosanoids: mediators and therapeutic targets in fibrotic lung disease.
about
Effect of allergy and inflammation on eicosanoid gene expression in CFTR deficiency.Pulmonary delivery of docosahexaenoic acid mitigates bleomycin-induced pulmonary fibrosisCyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosisPulmonary hypertension in parenchymal lung disease.Epithelial-mesenchymal interactions in pulmonary fibrosis.Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapyTowards systems biology of human pulmonary fibrosis.CD36, but not G2A, modulates efferocytosis, inflammation, and fibrosis following bleomycin-induced lung injury.Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots.Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time?Curcumin attenuates radiation-induced inflammation and fibrosis in rat lungs.Opposing roles of leukotrienes and prostaglandins in fibrotic lung disease.Pulmonary hypertension in idiopathic pulmonary fibrosis: a review.Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury.Control of experimental pulmonary tuberculosis depends more on immunostimulatory leukotrienes than on the absence of immunosuppressive prostaglandins.24-Hour Hypoxia and Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis.Characterization and modulation of canine mast cell derived eicosanoids.Regulation of human microsomal prostaglandin E synthase-1 by IL-1β requires a distal enhancer element with a unique role for C/EBPβ.Involvement of leukotrienes in the pathogenesis of silica-induced pulmonary fibrosis in mice.Effect of leukotriene receptor antagonists on lung fibrosis in rats.Untargeted serum metabonomics study of psoriasis vulgaris based on ultra-performance liquid chromatography coupled to mass spectrometry.Leishmania infantum lipophosphoglycan induced-Prostaglandin E2 production in association with PPAR-γ expression via activation of Toll like receptors-1 and 2.
P2860
Q33863162-C9831DAC-1925-404C-84ED-E99D9992AF1EQ35151307-3307B1BD-58BB-4E02-B0E9-E801A6CC3B8EQ36013692-9F47018A-CDF9-44EE-8A3A-930041C6AB54Q36328903-00B0DE5E-30E7-4197-A322-362EFC564F29Q36427136-28268C5B-A93B-4854-813A-8521A1947ACDQ36440438-E7486959-CC6B-4183-807A-3AFF0748ABB9Q36698826-3630E161-9423-41E8-AD4A-6A4849F95000Q36709598-79933974-1969-49FE-9F0E-E18E77997C53Q36719113-3E17A796-282F-45EF-AE78-832FECEDB59AQ36970702-CB0F4C05-6FFC-4EE0-BA82-E40C4584CFA6Q37090078-F6F34837-EAD6-44BE-8E7C-3EE1B10E5E6CQ37754750-03A0BE37-2C46-4828-A58C-3D2E6E5AE4D8Q37890199-EC8E2D37-4723-40A5-8A06-F820623AF2DCQ40324025-5A38A5E4-0C97-47A7-A10E-51DFD34724D2Q41774199-B303E690-70C1-46E5-83C9-ADE0D686527AQ41855992-F3B2F714-E8C5-4EAD-BBBD-63C95F8D3919Q42079944-07CAB076-524E-4BE0-A2A2-26BD7CA2CE76Q42500812-C68A2DB4-45A4-4406-8D50-60EFBC840DA8Q43055697-9A28294A-9282-4944-819C-A39A04DF0639Q46820455-8353DDD3-E394-4EF5-92B8-9328999C2B55Q47126973-38192E4A-FD73-479A-A1EE-FFD5E7B56DCBQ47131860-225FB3EC-1FE9-4F1B-B094-BA34991230E0
P2860
Eicosanoids: mediators and therapeutic targets in fibrotic lung disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Eicosanoids: mediators and therapeutic targets in fibrotic lung disease.
@ast
Eicosanoids: mediators and therapeutic targets in fibrotic lung disease.
@en
type
label
Eicosanoids: mediators and therapeutic targets in fibrotic lung disease.
@ast
Eicosanoids: mediators and therapeutic targets in fibrotic lung disease.
@en
prefLabel
Eicosanoids: mediators and therapeutic targets in fibrotic lung disease.
@ast
Eicosanoids: mediators and therapeutic targets in fibrotic lung disease.
@en
P356
P1433
P1476
Eicosanoids: mediators and therapeutic targets in fibrotic lung disease.
@en
P2093
Ryan P Charbeneau
P304
P356
10.1042/CS20050012
P407
P577
2005-06-01T00:00:00Z